GeneDx Holdings Investors Can Lead Securities Fraud Lawsuit

Rosen Law Firm is urging purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, to file for lead plaintiff status in a securities fraud lawsuit. The deadline for eligible investors to apply with the court is August 3, 2026.

The lawsuit alleges that the company made misrepresentations and omissions regarding the impact of its acquisition of Fabric on GeneDx's overall business and financials. According to the complaint, GeneDx repeatedly stated that the Fabric acquisition would improve its financial results and create operational efficiencies. However, the lawsuit claims that defendants were aware of, or disregarded, significant issues with Fabric that negatively impacted GeneDx's business.

When the true details of Fabric's viability became public, investors allegedly suffered damages. Rosen Law Firm, which specializes in securities class actions, is encouraging investors who purchased GeneDx stock during the class period to contact them for information about potentially seeking compensation without out-of-pocket costs.

Investors who wish to serve as lead plaintiff must move the court by the August 3 deadline. A lead plaintiff acts as a representative party for the class in directing the litigation. No class has yet been certified in the action, and investors are not required to retain counsel to participate.